CDEK
← All drugs Report issue

tasosartan

Small moleculeexperimental

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Mechanism of action

  • Type-1 angiotensin II receptorANTAGONIST

    AGTR1 antagonist

    This drug is sequentially metabolized by the P450 enzyme system, first to form a hydroxy-intermediate that is then biotransformed to enoltasosartan, another active compound that presents in vitro a higher affinity for the AngII subtype-1 receptors than the parent compound.

Chemistry & pharmacology

Loading structure…

SMILES

Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2
Mol. weight
411.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ana756
  • ana-756
  • tasosartan
  • tasosartan
  • tasosartan
  • tasosartan
  • tasosartan
  • tasosartan
  • tasosartan
  • verdia